Skip to main content

Persistent Disease clinical trials at UCSF
1 in progress, 0 open to new patients

  • Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer

    Sorry, in progress, not accepting new patients

    This phase II trial studies how well brivanib alaninate works in treating patients with cervical cancer that has come back. Brivanib alaninate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.

    San Francisco, California and other locations

Last updated: